COMMUNIQUÉS West-GlobeNewswire

BrainsWay to Report First Quarter 2026 Financial Results on May 13, 2026
29/04/2026
BURLINGTON, Mass. and JERUSALEM, April 29, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation technologies, today [...]
SkinHealth Systems to Report First Quarter 2026 Financial Results on May 7, 2026
29/04/2026
LONG BEACH, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems Inc. (formerly The Beauty Health Company; Nasdaq: SKIN), a global medical aesthetics company, today announced it will report first quarter 2026 [...]
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
29/04/2026
EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA submission in Q4 2026 NEEDHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Candel [...]
Beacon Therapeutics Annouces Presentations at the ARVO 2026 Annual Meeting
29/04/2026
LONDON and CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (Beacon Therapeutics or the Company), a leading clinical-stage biotechnology company with a mission to save and [...]
Imviva Biotech to Present Clinical Data from Ongoing Phase 1/2 Study of CTA313 at the American Society of Gene & Cell Therapy's Annual Meeting
29/04/2026
Dual-targeted allogeneic CAR-T therapy demonstrates immune-reset mechanism and durable remission in system lupus erythematosus BOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology [...]
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
29/04/2026
Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate TPST-2003 Results support clinical benefit of parallel-structure dual-targeting CAR [...]
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
29/04/2026
Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory Momentum Seven Approved Phase 2a Human Clinical Trials Expected to Begin Patient [...]
CMR Surgical Submits 510(k) Application to U.S. FDA to Expand Versius Plus™ into Gynecology
29/04/2026
PRESS RELEASE Following Recent FDA Clearance for Cholecystectomy, the Company is now 510(k) pending for Gynecology. This Submission Builds On Extensive Global Clinical Experience in Gynecology and Continues CMR’s U.S. [...]
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
29/04/2026
New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial’s precision-medicine approach GLEN ALLEN, Va., April 29, 2026 ( [...]
Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
29/04/2026
Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment SARASOTA, Fla, April 29, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: [...]
Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
29/04/2026
THE WOODLANDS, TX, April 29, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for Irritable Bowel Syndrome
29/04/2026
Funds will support one of the largest interventional clinical trials of a full-spectrum microbiome product, and the largest ever to be conducted in IBS Dosing of first patient of the Phase 2b ‘RISE’ trial anticipated in [...]
Laguna Announces FDA Clearance of IND Application for LGNA-100, a Novel γδ T Cell Activator for High-Risk Pediatric Leukemias
29/04/2026
SAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) -- Laguna Biotherapeutics, Inc. (Laguna), a clinical-stage biotechnology company focused on novel live bacterial therapeutics, today announced that the U.S. Food and Drug [...]
Doheny Eye Institute Researchers to Share Cutting-Edge Vision Science Across More Than 20 Sessions at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting
29/04/2026
Doheny scientists, clinician-scientists, and research fellows will present findings on eye disease, advanced imaging, artificial intelligence and more at the preeminent global vision research conference PASADENA, Calif [...]
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
29/04/2026
DALLAS, April 29, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene [...]
Codexis to share RNA manufacturing advances at TIDES USA
29/04/2026
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, will present new data on ECO [...]
TOMI Environmental Solutions Targets $70 Billion U.S. Drone and Defense Budget with Autonomous SteraMist iHP Decontamination
29/04/2026
Strategic Initiative Focuses on Automated Biological and Chemical Defense for Land, Air, Sea, and Space FREDERICK, Md., April 29, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a [...]
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
29/04/2026
MOUNTAIN VIEW, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies and commercializing [...]
Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market
29/04/2026
Sangamo’s common stock to transition trading from The Nasdaq Capital Market to OTCQB Venture Market beginning May 5, 2026 RICHMOND, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a [...]

Pages